A Study to Investigate the Antihypertensive Efficacy of MK0954

• Status: Completed
• Trial end date: 1992-11-01
• Target enrollment: 0
• Participant gender: All

Summary

After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks. This study evaluated if losartan is more effective than placebo in lowering sitting diastolic blood pressure and is well tolerated in patients with mild to moderate hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Antihypertensive Agents; Losartan

Criteria

Inclusion Criteria:

• Patient has been diagnosed with mild to moderate hypertension (SDBP 95-115 mm Hg)

• Patient has no medical problems or treatments that might effect their blood pressure

Exclusion Criteria:

• Pregnant or lactating females

• Patient has secondary hypertension or malignant hypertension

• Sitting systolic blood pressure > 210 mm Hg

• History of stroke

• History of myocardial infarction with in past year

• Current or prior history of heart failure

• Known hypersensitivity to losartan

• Prior exposure to losartan

• Patients known to be HIV positive

• Patient is abusing or has abused alcohol or other drugs within the past 4 years